Genelux Corporation (NASDAQ: GNLX) Stock Competitors & Peer Comparison
See GNLX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GNLX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GNLX | $2.72 | -0.73% | 122M | -3.20 | -$0.85 | N/A |
| VRTX | $548.05 | +1.44% | 139.1B | 28.80 | $19.03 | N/A |
| REGN | $834.04 | +0.90% | 85.9B | 18.28 | $45.63 | +0.44% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,039.78 | +0.16% | 64.7B | 93.84 | $11.08 | N/A |
| MRNA | $145.13 | +8.86% | 57.6B | -17.81 | -$8.15 | N/A |
| RVMDW | $11.80 | -3.83% | 46.3B | -1.64 | -$7.21 | N/A |
| RVMD | $209.46 | -1.07% | 44.5B | -23.75 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $374.47 | +1.44% | 40B | 65.93 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
GNLX vs VRTX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, VRTX has a market cap of 139.1B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while VRTX trades at $548.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas VRTX's P/E ratio is 28.80. In terms of profitability, GNLX's ROE is -1.95%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, GNLX is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
GNLX vs REGN Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, REGN has a market cap of 85.9B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while REGN trades at $834.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas REGN's P/E ratio is 18.28. In terms of profitability, GNLX's ROE is -1.95%, compared to REGN's ROE of +0.14%. Regarding short-term risk, GNLX is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
GNLX vs VRNA Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas VRNA's P/E ratio is -102.80. In terms of profitability, GNLX's ROE is -1.95%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, GNLX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
GNLX vs ARGX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, ARGX has a market cap of 64.7B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while ARGX trades at $1,039.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas ARGX's P/E ratio is 93.84. In terms of profitability, GNLX's ROE is -1.95%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, GNLX is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
GNLX vs MRNA Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, MRNA has a market cap of 57.6B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while MRNA trades at $145.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas MRNA's P/E ratio is -17.81. In terms of profitability, GNLX's ROE is -1.95%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, GNLX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
GNLX vs RVMDW Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, RVMDW has a market cap of 46.3B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while RVMDW trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas RVMDW's P/E ratio is -1.64. In terms of profitability, GNLX's ROE is -1.95%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, GNLX is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
GNLX vs RVMD Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, RVMD has a market cap of 44.5B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while RVMD trades at $209.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas RVMD's P/E ratio is -23.75. In terms of profitability, GNLX's ROE is -1.95%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, GNLX is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
GNLX vs SGEN Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas SGEN's P/E ratio is -57.19. In terms of profitability, GNLX's ROE is -1.95%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, GNLX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
GNLX vs ONC Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, ONC has a market cap of 40B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while ONC trades at $374.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas ONC's P/E ratio is 65.93. In terms of profitability, GNLX's ROE is -1.95%, compared to ONC's ROE of +0.14%. Regarding short-term risk, GNLX is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
GNLX vs ALNY Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, ALNY has a market cap of 31.6B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while ALNY trades at $236.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas ALNY's P/E ratio is 42.56. In terms of profitability, GNLX's ROE is -1.95%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, GNLX is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
GNLX vs BNTX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, BNTX has a market cap of 29.3B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while BNTX trades at $116.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas BNTX's P/E ratio is -15.12. In terms of profitability, GNLX's ROE is -1.95%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, GNLX is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
GNLX vs INSM Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, INSM has a market cap of 27.3B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while INSM trades at $125.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas INSM's P/E ratio is -30.60. In terms of profitability, GNLX's ROE is -1.95%, compared to INSM's ROE of -1.11%. Regarding short-term risk, GNLX is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
GNLX vs ROIV Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, ROIV has a market cap of 26.2B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while ROIV trades at $36.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas ROIV's P/E ratio is -34.53. In terms of profitability, GNLX's ROE is -1.95%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, GNLX is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
GNLX vs INCY Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, INCY has a market cap of 25.9B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while INCY trades at $127.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas INCY's P/E ratio is 17.18. In terms of profitability, GNLX's ROE is -1.95%, compared to INCY's ROE of +0.30%. Regarding short-term risk, GNLX is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
GNLX vs UTHR Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, UTHR has a market cap of 21.8B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while UTHR trades at $513.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas UTHR's P/E ratio is 18.36. In terms of profitability, GNLX's ROE is -1.95%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, GNLX is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
GNLX vs GMAB Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, GMAB has a market cap of 20.5B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while GMAB trades at $33.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas GMAB's P/E ratio is 25.21. In terms of profitability, GNLX's ROE is -1.95%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, GNLX is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
GNLX vs BGNE Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas BGNE's P/E ratio is -22.55. In terms of profitability, GNLX's ROE is -1.95%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, GNLX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
GNLX vs DNA-WT Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, GNLX's ROE is -1.95%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, GNLX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
GNLX vs JAZZ Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, JAZZ has a market cap of 16B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while JAZZ trades at $254.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas JAZZ's P/E ratio is 9.48. In terms of profitability, GNLX's ROE is -1.95%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, GNLX is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
GNLX vs BBIO Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, BBIO has a market cap of 16B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while BBIO trades at $81.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas BBIO's P/E ratio is -21.79. In terms of profitability, GNLX's ROE is -1.95%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, GNLX is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
GNLX vs ASND Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, ASND has a market cap of 15.7B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while ASND trades at $253.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas ASND's P/E ratio is -104.67. In terms of profitability, GNLX's ROE is -1.95%, compared to ASND's ROE of +1.90%. Regarding short-term risk, GNLX is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
GNLX vs NBIX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, NBIX has a market cap of 15.3B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while NBIX trades at $152.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas NBIX's P/E ratio is 22.05. In terms of profitability, GNLX's ROE is -1.95%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, GNLX is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check NBIX's competition here
Exelixis, Inc. (NASDAQ: EXEL)
GNLX vs EXEL Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, EXEL has a market cap of 13.6B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while EXEL trades at $54.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas EXEL's P/E ratio is 15.45. In terms of profitability, GNLX's ROE is -1.95%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, GNLX is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check EXEL's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
GNLX vs BMRN Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, BMRN has a market cap of 12.9B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while BMRN trades at $66.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas BMRN's P/E ratio is 32.07. In terms of profitability, GNLX's ROE is -1.95%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, GNLX is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check BMRN's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
GNLX vs HALO Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, HALO has a market cap of 12.8B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while HALO trades at $108.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas HALO's P/E ratio is 20.18. In terms of profitability, GNLX's ROE is -1.95%, compared to HALO's ROE of +1.81%. Regarding short-term risk, GNLX is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check HALO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
GNLX vs KRTX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas KRTX's P/E ratio is -28.09. In terms of profitability, GNLX's ROE is -1.95%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, GNLX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
GNLX vs ARWR Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, ARWR has a market cap of 12.3B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while ARWR trades at $87.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas ARWR's P/E ratio is -38.72. In terms of profitability, GNLX's ROE is -1.95%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, GNLX is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
GNLX vs MDGL Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while MDGL trades at $516.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas MDGL's P/E ratio is -40.37. In terms of profitability, GNLX's ROE is -1.95%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, GNLX is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
GNLX vs TECH Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while TECH trades at $72.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas TECH's P/E ratio is 37.28. In terms of profitability, GNLX's ROE is -1.95%, compared to TECH's ROE of +0.09%. Regarding short-term risk, GNLX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
GNLX vs RNAM Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas RNAM's P/E ratio is -17.39. In terms of profitability, GNLX's ROE is -1.95%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, GNLX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
GNLX vs AXSM Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, AXSM has a market cap of 10.7B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while AXSM trades at $207.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas AXSM's P/E ratio is -54.25. In terms of profitability, GNLX's ROE is -1.95%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, GNLX is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check AXSM's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
GNLX vs SMMT Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, SMMT has a market cap of 10.5B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while SMMT trades at $13.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas SMMT's P/E ratio is -11.75. In terms of profitability, GNLX's ROE is -1.95%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, GNLX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check SMMT's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
GNLX vs PRAX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, PRAX has a market cap of 10.5B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while PRAX trades at $375.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas PRAX's P/E ratio is -29.08. In terms of profitability, GNLX's ROE is -1.95%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, GNLX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check PRAX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
GNLX vs KRYS Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, KRYS has a market cap of 10.2B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while KRYS trades at $346.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas KRYS's P/E ratio is 43.43. In terms of profitability, GNLX's ROE is -1.95%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, GNLX is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check KRYS's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
GNLX vs PTGX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, PTGX has a market cap of 9.9B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while PTGX trades at $154.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas PTGX's P/E ratio is 149.90. In terms of profitability, GNLX's ROE is -1.95%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, GNLX is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check PTGX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
GNLX vs IONS Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, IONS has a market cap of 9.9B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while IONS trades at $59.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas IONS's P/E ratio is -34.73. In terms of profitability, GNLX's ROE is -1.95%, compared to IONS's ROE of -1.11%. Regarding short-term risk, GNLX is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check IONS's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
GNLX vs KYMR Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, KYMR has a market cap of 9.9B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while KYMR trades at $119.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas KYMR's P/E ratio is -37.44. In terms of profitability, GNLX's ROE is -1.95%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, GNLX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check KYMR's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
GNLX vs CYTK Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while CYTK trades at $76.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas CYTK's P/E ratio is -10.64. In terms of profitability, GNLX's ROE is -1.95%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, GNLX is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
GNLX vs RXDX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas RXDX's P/E ratio is -56.47. In terms of profitability, GNLX's ROE is -1.95%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, GNLX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check RXDX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
GNLX vs SYRE Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, SYRE has a market cap of 9.2B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while SYRE trades at $106.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas SYRE's P/E ratio is -54.61. In terms of profitability, GNLX's ROE is -1.95%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, GNLX is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check SYRE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
GNLX vs IMVT Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, IMVT has a market cap of 9.2B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while IMVT trades at $44.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas IMVT's P/E ratio is -15.73. In terms of profitability, GNLX's ROE is -1.95%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, GNLX is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check IMVT's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
GNLX vs NUVL Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas NUVL's P/E ratio is -21.79. In terms of profitability, GNLX's ROE is -1.95%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, GNLX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check NUVL's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
GNLX vs PCVX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, PCVX has a market cap of 9B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while PCVX trades at $62.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas PCVX's P/E ratio is -8.21. In terms of profitability, GNLX's ROE is -1.95%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, GNLX is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check PCVX's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
GNLX vs CRNX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while CRNX trades at $84.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas CRNX's P/E ratio is -16.80. In terms of profitability, GNLX's ROE is -1.95%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, GNLX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check CRNX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
GNLX vs IMGN Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas IMGN's P/E ratio is -111.55. In terms of profitability, GNLX's ROE is -1.95%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, GNLX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check IMGN's competition here
Abivax S.A. (NASDAQ: ABVX)
GNLX vs ABVX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, ABVX has a market cap of 8.4B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while ABVX trades at $114.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas ABVX's P/E ratio is -60.25. In terms of profitability, GNLX's ROE is -1.95%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, GNLX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check ABVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
GNLX vs BPMC Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas BPMC's P/E ratio is -51.58. In terms of profitability, GNLX's ROE is -1.95%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, GNLX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
GNLX vs APGE Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while APGE trades at $134.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas APGE's P/E ratio is -31.12. In terms of profitability, GNLX's ROE is -1.95%, compared to APGE's ROE of -0.30%. Regarding short-term risk, GNLX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check APGE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
GNLX vs TGTX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while TGTX trades at $54.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas TGTX's P/E ratio is 19.66. In terms of profitability, GNLX's ROE is -1.95%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, GNLX is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check TGTX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
GNLX vs CERE Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas CERE's P/E ratio is -16.47. In terms of profitability, GNLX's ROE is -1.95%, compared to CERE's ROE of -0.72%. Regarding short-term risk, GNLX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check CERE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
GNLX vs IBRX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, IBRX has a market cap of 8.2B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while IBRX trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas IBRX's P/E ratio is -8.03. In terms of profitability, GNLX's ROE is -1.95%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, GNLX is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check IBRX's competition here
Alkermes plc (NASDAQ: ALKS)
GNLX vs ALKS Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, ALKS has a market cap of 8.1B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while ALKS trades at $48.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas ALKS's P/E ratio is 50.87. In terms of profitability, GNLX's ROE is -1.95%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, GNLX is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check ALKS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
GNLX vs RYTM Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, RYTM has a market cap of 7.5B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while RYTM trades at $110.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas RYTM's P/E ratio is -35.35. In terms of profitability, GNLX's ROE is -1.95%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, GNLX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check RYTM's competition here
Metsera, Inc. (NASDAQ: MTSR)
GNLX vs MTSR Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas MTSR's P/E ratio is -23.58. In terms of profitability, GNLX's ROE is -1.95%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, GNLX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
GNLX vs CAI Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, CAI has a market cap of 6.9B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while CAI trades at $26.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas CAI's P/E ratio is 69.06. In terms of profitability, GNLX's ROE is -1.95%, compared to CAI's ROE of +0.19%. Regarding short-term risk, GNLX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check CAI's competition here
CG Oncology Inc. (NASDAQ: CGON)
GNLX vs CGON Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, CGON has a market cap of 6.8B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while CGON trades at $79.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas CGON's P/E ratio is -28.85. In terms of profitability, GNLX's ROE is -1.95%, compared to CGON's ROE of -0.25%. Regarding short-term risk, GNLX is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check CGON's competition here
Merus N.V. (NASDAQ: MRUS)
GNLX vs MRUS Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas MRUS's P/E ratio is -17.05. In terms of profitability, GNLX's ROE is -1.95%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, GNLX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check MRUS's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
GNLX vs SRRK Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, SRRK has a market cap of 6.8B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while SRRK trades at $56.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas SRRK's P/E ratio is -16.38. In terms of profitability, GNLX's ROE is -1.95%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, GNLX is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check SRRK's competition here
Arcellx, Inc. (NASDAQ: ACLX)
GNLX vs ACLX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas ACLX's P/E ratio is -28.27. In terms of profitability, GNLX's ROE is -1.95%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, GNLX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
GNLX vs RETA Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas RETA's P/E ratio is -66.29. In terms of profitability, GNLX's ROE is -1.95%, compared to RETA's ROE of +0.47%. Regarding short-term risk, GNLX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check RETA's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
GNLX vs ORKA Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, ORKA has a market cap of 6.5B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while ORKA trades at $107.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas ORKA's P/E ratio is -55.65. In terms of profitability, GNLX's ROE is -1.95%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, GNLX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check ORKA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
GNLX vs BLTE Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while BLTE trades at $161.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas BLTE's P/E ratio is -86.13. In terms of profitability, GNLX's ROE is -1.95%, compared to BLTE's ROE of -0.21%. Regarding short-term risk, GNLX is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check BLTE's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
GNLX vs CNTA Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas CNTA's P/E ratio is -22.63. In terms of profitability, GNLX's ROE is -1.95%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, GNLX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check CNTA's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
GNLX vs DNTH Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, DNTH has a market cap of 6.2B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while DNTH trades at $111.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas DNTH's P/E ratio is -26.77. In terms of profitability, GNLX's ROE is -1.95%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, GNLX is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check DNTH's competition here
Erasca, Inc. (NASDAQ: ERAS)
GNLX vs ERAS Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, ERAS has a market cap of 6.1B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while ERAS trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas ERAS's P/E ratio is -18.96. In terms of profitability, GNLX's ROE is -1.95%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, GNLX is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check ERAS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
GNLX vs TVTX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while TVTX trades at $65.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas TVTX's P/E ratio is -146.02. In terms of profitability, GNLX's ROE is -1.95%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, GNLX is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check TVTX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
GNLX vs COGT Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, COGT has a market cap of 6B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while COGT trades at $36.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas COGT's P/E ratio is -16.73. In terms of profitability, GNLX's ROE is -1.95%, compared to COGT's ROE of -0.73%. Regarding short-term risk, GNLX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check COGT's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
GNLX vs DFTX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, DFTX has a market cap of 6B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while DFTX trades at $44.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas DFTX's P/E ratio is N/A. In terms of profitability, GNLX's ROE is -1.95%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, GNLX is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check DFTX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
GNLX vs XENE Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, XENE has a market cap of 5.9B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while XENE trades at $60.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas XENE's P/E ratio is -12.93. In terms of profitability, GNLX's ROE is -1.95%, compared to XENE's ROE of -0.44%. Regarding short-term risk, GNLX is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check XENE's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
GNLX vs MIRM Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, MIRM has a market cap of 5.9B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while MIRM trades at $96.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas MIRM's P/E ratio is -6.62. In terms of profitability, GNLX's ROE is -1.95%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, GNLX is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check MIRM's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
GNLX vs PTCT Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, PTCT has a market cap of 5.8B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while PTCT trades at $69.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas PTCT's P/E ratio is -29.97. In terms of profitability, GNLX's ROE is -1.95%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, GNLX is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check PTCT's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
GNLX vs LGND Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while LGND trades at $286.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas LGND's P/E ratio is 31.43. In terms of profitability, GNLX's ROE is -1.95%, compared to LGND's ROE of +0.20%. Regarding short-term risk, GNLX is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
GNLX vs CDTX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas CDTX's P/E ratio is -19.77. In terms of profitability, GNLX's ROE is -1.95%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, GNLX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check CDTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
GNLX vs CRSP Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, CRSP has a market cap of 5.6B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while CRSP trades at $59.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas CRSP's P/E ratio is -12.21. In terms of profitability, GNLX's ROE is -1.95%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, GNLX is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check CRSP's competition here
Abcam plc (NASDAQ: ABCM)
GNLX vs ABCM Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, GNLX's ROE is -1.95%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, GNLX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
GNLX vs ISEE Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas ISEE's P/E ratio is -22.44. In terms of profitability, GNLX's ROE is -1.95%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, GNLX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
GNLX vs APLS Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas APLS's P/E ratio is 38.35. In terms of profitability, GNLX's ROE is -1.95%, compared to APLS's ROE of +0.40%. Regarding short-term risk, GNLX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check APLS's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
GNLX vs ACAD Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, ACAD has a market cap of 5.1B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while ACAD trades at $29.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas ACAD's P/E ratio is 13.29. In terms of profitability, GNLX's ROE is -1.95%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, GNLX is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
GNLX vs DYN Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, DYN has a market cap of 4.9B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while DYN trades at $26.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas DYN's P/E ratio is -8.11. In terms of profitability, GNLX's ROE is -1.95%, compared to DYN's ROE of -0.64%. Regarding short-term risk, GNLX is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check DYN's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
GNLX vs TERN Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas TERN's P/E ratio is -51.41. In terms of profitability, GNLX's ROE is -1.95%, compared to TERN's ROE of -0.20%. Regarding short-term risk, GNLX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check TERN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
GNLX vs EWTX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while EWTX trades at $44.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas EWTX's P/E ratio is -23.88. In terms of profitability, GNLX's ROE is -1.95%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, GNLX is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check EWTX's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
GNLX vs PBLS Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, PBLS has a market cap of 4.6B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while PBLS trades at $39.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas PBLS's P/E ratio is -44.73. In terms of profitability, GNLX's ROE is -1.95%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, GNLX is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check PBLS's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
GNLX vs FOLD Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas FOLD's P/E ratio is -161.00. In terms of profitability, GNLX's ROE is -1.95%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, GNLX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
GNLX vs AKRO Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas AKRO's P/E ratio is -14.57. In terms of profitability, GNLX's ROE is -1.95%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, GNLX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
GNLX vs ALPN Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas ALPN's P/E ratio is -101.52. In terms of profitability, GNLX's ROE is -1.95%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, GNLX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check ALPN's competition here
Celcuity Inc. (NASDAQ: CELC)
GNLX vs CELC Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, CELC has a market cap of 4.4B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while CELC trades at $93.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas CELC's P/E ratio is -21.06. In terms of profitability, GNLX's ROE is -1.95%, compared to CELC's ROE of -3.51%. Regarding short-term risk, GNLX is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check CELC's competition here
Veradermics, Incorporated (NYSE: MANE)
GNLX vs MANE Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, MANE has a market cap of 4.3B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while MANE trades at $102.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas MANE's P/E ratio is -32.79. In terms of profitability, GNLX's ROE is -1.95%, compared to MANE's ROE of -0.29%. Regarding short-term risk, GNLX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check MANE's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
GNLX vs AMLX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, AMLX has a market cap of 4.3B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while AMLX trades at $38.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas AMLX's P/E ratio is -25.77. In terms of profitability, GNLX's ROE is -1.95%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, GNLX is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check AMLX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
GNLX vs ELVN Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, ELVN has a market cap of 4.3B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while ELVN trades at $59.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas ELVN's P/E ratio is -35.82. In terms of profitability, GNLX's ROE is -1.95%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, GNLX is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check ELVN's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
GNLX vs RLAY Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, RLAY has a market cap of 4.3B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while RLAY trades at $19.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas RLAY's P/E ratio is -12.38. In terms of profitability, GNLX's ROE is -1.95%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, GNLX is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for GNLX.Check RLAY's competition here
Opthea Limited (NASDAQ: OPT)
GNLX vs OPT Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas OPT's P/E ratio is -1.52. In terms of profitability, GNLX's ROE is -1.95%, compared to OPT's ROE of +1.18%. Regarding short-term risk, GNLX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
GNLX vs PRTC Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas PRTC's P/E ratio is -3.78. In terms of profitability, GNLX's ROE is -1.95%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, GNLX is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check PRTC's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
GNLX vs ADPT Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, ADPT has a market cap of 4.2B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while ADPT trades at $25.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas ADPT's P/E ratio is -63.39. In terms of profitability, GNLX's ROE is -1.95%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, GNLX is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check ADPT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
GNLX vs MRTX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas MRTX's P/E ratio is -4.82. In terms of profitability, GNLX's ROE is -1.95%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, GNLX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check MRTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
GNLX vs LEGN Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, LEGN has a market cap of 4B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while LEGN trades at $21.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas LEGN's P/E ratio is -32.09. In terms of profitability, GNLX's ROE is -1.95%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, GNLX is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check LEGN's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
GNLX vs DNLI Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, DNLI has a market cap of 4B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while DNLI trades at $24.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas DNLI's P/E ratio is -8.65. In terms of profitability, GNLX's ROE is -1.95%, compared to DNLI's ROE of -0.55%. Regarding short-term risk, GNLX is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check DNLI's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
GNLX vs VKTX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while VKTX trades at $33.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas VKTX's P/E ratio is -7.27. In terms of profitability, GNLX's ROE is -1.95%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, GNLX is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check VKTX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
GNLX vs TNGX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while TNGX trades at $23.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas TNGX's P/E ratio is -28.77. In terms of profitability, GNLX's ROE is -1.95%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, GNLX is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check TNGX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
GNLX vs CPRX Comparison August 2026
Genelux Corporation (NASDAQ: GNLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNLX stands at 122M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, GNLX is priced at $2.72 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNLX currently has a P/E ratio of -3.20, whereas CPRX's P/E ratio is 12.30. In terms of profitability, GNLX's ROE is -1.95%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, GNLX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for GNLX.Check CPRX's competition here